Navigation Links
Anadys Highlights ANA773 Data to be Presented at ASCO
Date:5/25/2011

advanced solid tumors were treated with ANA773 every-other-day (QOD) for 14 days, followed by a 14 day rest period, on continuous 28 day cycles.  20 patients participated in the study and were treated at dose levels of either 50mg, 100mg, 200mg, 400mg or 800mg (all QOD), with a minimum of three patients enrolled at each dose level. The endpoints for the study included safety, pharmacokinetics, biomarkers of immune activation and preliminary assessment of tumor response by RECIST.  

Next Steps for ANA773 Development

Anadys is advancing development of ANA773 in a separate indication, chronic hepatitis C virus infection, or HCV.  Anadys is currently preparing for a Phase IIa study of ANA773 in combination with ribavirin in HCV patients, which it expects to initiate in Europe this quarter.  The Company expects to receive 28-day data from the Phase IIa HCV study during the fourth quarter of this year.

About TLR7 agonists in cancer therapy

The potential benefits of the TLR7 mechanism in cancer therapy arise from the fundamental role of this receptor in immune activation.  The host immune system, once activated, plays an essential role in controlling the ability of cancer cells to grow, invade and metastasize.  Immunotherapy has had some success in treating selected tumors, and the potential to harness the immune system as a therapeutic modality remains of great interest to many oncologists.

TLR7 agonists are of particular interest because there is precedent for their use in cancer. Small molecule ligands for this receptor have been identified, including topical imiquimod (Aldara®) which is approved for the treatment of basal cell carcinoma in the United States. Imiquimod and other TLR7 agonists have also demonstrated early clinical activity against other tumor types, including melanoma and chronic lymphocytic leukemia. 

About Anadys

Anadys
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Lawrence Livermore scientists ... Thomson Reuters list of " The World's Most Influential ... of the 3,000 researchers who were identified by analyzing ... those who published the highest-impact work (2002-2012 and 2012-2013). ... on combustion modeling . , "This recognition is ...
(Date:7/25/2014)... TEL AVIV, Israel , July 25, 2014 /PRNewswire/ ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, today announced financial ... First Half 2014 Financial Summary: , Reported ... 30, 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
(Date:7/25/2014)... July 25, 2014 At the request ... granted a 60-day extension for the public comment period ... Rule for Model Aircraft established by Congress as part ... The 60-day extension establishes the new deadline for comments ... Department of Transportation/FAA notice published in the Federal Register ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3FAA Grants Comment Extension at the Request of AMA 2
... Key words: ... Imaging Beads, , ... pro-inflammatory cytokines with potent leukocyte activation and/or chemotactic activity in ... C, and CXC3) based on the number and sequential relationship of ...
... J. Chartier and H.C. Birnboim , DNA Genotek Inc., ... DNA collected with Oragene works well with TaqMan SNP Genotyping Assays. , ... detected., , ... Single-nucleotide polymorphisms (SNPs) are highly abundant, and are estimated , ...
... , , ... Research Organics, Inc.is an ISO 9001:2000 primary manufacturer and leading ... for molecular biology, , diagnostics, cell culture, ... , Founded in 1953, Research Organics pioneered manufacture ...
Cached Biology Technology:The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 2The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 3The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 4Oragene is compatible with TaqMan SNP genotyping 2Oragene is compatible with TaqMan SNP genotyping 3Research Organics 2Research Organics 3
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... similar counterparts in humans, affect the connections between nerve ... the hippocampus, an area of the brain that plays ... of memories. The results of the study have been ... function depends on the active communication between nerve cells, ... together into a dense network where they constantly relay ...
(Date:7/24/2014)... 24, 2014) For years, researchers and patients have ... any cell type in the bodycould provide insight into ... Yet progress has been hampered by the inability to ... their human counterparts, in part because human ESCs are ... , Now Thorold Theunissen, Benjamin Powell, and Haoyi Wang, ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... dark scene, attention brings to mind specific details of our ... at the Salk Institute for Biological Studies shows that the ... for its role in the control of eye and head ... findings, published in the Dec. 20, 2009, issue of the ...
... in an antibiotic-resistant bacterium is cause for concern, according ... Faculty of 1000 member Dr Johann Pitout, of ... Calgary, urges the medical community to monitor the spread ... to use more powerful antibiotics as a first response. ...
... UCLA scientists have identified a molecular switch that prevents ... 24 edition of the journal Neuron , the discovery ... ultimately leads to death in as little as 10 years. ... Americans, Huntington,s progressively deprives patients of their ability to walk, ...
Cached Biology News:Seeing without looking 2UCLA scientists find molecular switch to prevent Huntington's disease in mice 2